Scarica l'app Stockscreener
2.39
2.14%
0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ZNTL Giù?
Forum
Previsione
Precedente Chiudi:
$2.34
Aprire:
$2.34
Volume 24 ore:
245.06K
Relative Volume:
0.20
Capitalizzazione di mercato:
$154.75M
Reddito:
-
Utile/perdita netta:
$-292.19M
Rapporto P/E:
-0.5264
EPS:
-4.54
Flusso di cassa netto:
$-208.41M
1 W Prestazione:
+0.00%
1M Prestazione:
-31.32%
6M Prestazione:
+60.40%
1 anno Prestazione:
-1.65%
Intervallo 1D:
$2.34
$2.48
Intervallo di 1 settimana:
$2.21
$2.51
Portata 52W:
$1.01
$3.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Nome
Zentalis Pharmaceuticals Inc
Settore
Industria
Telefono
(858) 263-4333
Indirizzo
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
2.39 | 151.52M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-12 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2024-06-20 | Downgrade | UBS | Buy → Neutral |
| 2024-06-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-06-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Downgrade | Wedbush | Neutral → Underperform |
| 2024-06-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-11-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Iniziato | Cowen | Outperform |
| 2022-04-06 | Iniziato | Wells Fargo | Overweight |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-29 | Iniziato | Oppenheimer | Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-01-20 | Iniziato | Wedbush | Outperform |
| 2020-09-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-28 | Iniziato | Guggenheim | Buy |
| 2020-04-28 | Iniziato | Jefferies | Buy |
| 2020-04-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Zentalis Pharmaceuticals Inc Borsa (ZNTL) Ultime notizie
Is Zentalis Pharmaceuticals Inc. currently under institutional pressure2025 Volume Leaders & Risk Controlled Daily Trade Plans - mfd.ru
Don't Ignore The Insider Selling In Zentalis Pharmaceuticals - simplywall.st
Is Zentalis Pharmaceuticals Inc. forming a double bottomWeekly Stock Recap & AI Driven Stock Movement Reports - mfd.ru
Vincent Vultaggio Sells 29,951 Shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock - MarketBeat
Zentalis Pharmaceuticals PAO sells shares worth $97,556 By Investing.com - Investing.com Canada
Zentalis Pharma CMO Bruns sells $7998 in stock By Investing.com - Investing.com Canada
Zentalis Pharma CEO Eastland sells $21k in shares By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals PAO sells shares worth $97,556 - Investing.com
Will Zentalis Pharmaceuticals Inc. be affected by tariffsJuly 2025 Reactions & Fast Exit Strategy with Risk Control - mfd.ru
Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Tybourne Capital Management HK Ltd. - MarketBeat
Zentalis Pharmaceuticals PAO sells $7.8k in stock By Investing.com - Investing.com South Africa
Zentalis Pharmaceuticals PAO sells $7.8k in stock - Investing.com
Will Zentalis Pharmaceuticals Inc be affected by tariffsQuarterly Trade Review & Daily Technical Forecast Reports - baoquankhu1.vn
Zentalis to join NY Guggenheim Biotech investor summit - Stock Titan
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Stock Report: Is Zentalis Pharmaceuticals Inc currently under institutional pressureDay Trade & Smart Swing Trading Alerts - baoquankhu1.vn
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update - Defense World
Dow Update: How Zentalis Pharmaceuticals Inc stock reacts to job market data2025 Technical Patterns & Verified Swing Trading Watchlist - Bộ Nội Vụ
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Sahm
After-Hours Rally: Zentalis, LifeMD, And NanoViricides Among Top Gainers - Nasdaq
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying - Yahoo Finance
Zentalis Pharma Advances Stir Market as Azenosertib Program Strengthens - timothysykes.com
Zentalis outlines 2026 milestones for azenosertib program - The Globe and Mail
Zentalis Pharmaceuticals Surges After Promising Azenosertib Developments - StocksToTrade
Trade Recap: Will Zentalis Pharmaceuticals Inc stock outperform tech sector in 20252025 Performance Recap & Long-Term Safe Investment Plans - Bộ Nội Vụ
Zentalis Pharmaceuticals Surges with Azenosertib Developments - timothysykes.com
Group Walters Buys 6,459,973 Shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock - Defense World
Zentalis Pharmaceuticals, Inc. Provides Corporate Update on Azenosertib Development - TradingView — Track All Markets
Azenosertib plans at Zentalis (NASDAQ: ZNTL) with cash runway to 2027 - Stock Titan
Zentalis Pharmaceuticals Stock (ZNTL) Opinions on Azenosertib Development Update - Quiver Quantitative
Aug Weekly: Is Zentalis Pharmaceuticals Inc. stock ready for breakoutPortfolio Update Summary & Trade Opportunity Analysis Reports - ulpravda.ru
Major Investor Makes Bold Move on Zentalis Pharmaceuticals Stock - TipRanks
Is Zentalis Pharmaceuticals Inc. stock ready for breakoutGap Up & Low Risk Profit Maximizing Plans - Улправда
Insider Buying: Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Purchases 6,459,973 Shares of Stock - MarketBeat
Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m By Investing.com - Investing.com Nigeria
Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m - Investing.com
Is Zentalis Pharmaceuticals Inc. stock a top pick in earnings seasonWeekly Stock Report & Real-Time Volume Triggers - Улправда
Price Action: Will Zentalis Pharmaceuticals Inc. stock maintain momentum in 2025Quarterly Market Summary & Risk Adjusted Buy/Sell Alerts - Улправда
Will Zentalis Pharmaceuticals Inc. stock outperform tech sector in 2025Trade Risk Assessment & Risk Adjusted Buy and Sell Alerts - Улправда
Why analysts remain bullish on Zentalis Pharmaceuticals Inc. stockOil Prices & Risk Managed Investment Strategies - Улправда
Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners - Yahoo Finance
Zentalis Pharmaceuticals: Balancing DENALI Momentum and ASPENOVA Visibility Against Pivotal Data and Execution Risk (Hold Rating Maintained) - TipRanks
Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Zentalis Eyes A Pivotal 2026 As Azenosertib Advances Toward Potential Accelerated Approval - Nasdaq
ZNTL Pharmaceuticals Updates on Azenosertib Development - GuruFocus
What drives Zentalis Pharmaceuticals Inc stock priceGap Fill Strategies & Double Or Triple Capital - earlytimes.in
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 - MarketScreener
Zentalis Pharmaceuticals Provides Corporate Update and - GlobeNewswire
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Hold” by Brokerages - Defense World
Zentalis Pharmaceuticals Inc Azioni (ZNTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Zentalis Pharmaceuticals Inc Azioni (ZNTL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 09 '26 |
Sale |
2.39 |
335 |
802 |
33,332 |
| Vultaggio Vincent | PAO and PFO |
Feb 06 '26 |
Sale |
2.43 |
29,951 |
72,772 |
156,779 |
| Vultaggio Vincent | PAO and PFO |
Feb 10 '26 |
Sale |
2.42 |
6,894 |
16,699 |
146,506 |
| Vultaggio Vincent | PAO and PFO |
Feb 09 '26 |
Sale |
2.39 |
3,379 |
8,086 |
153,400 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 06 '26 |
Sale |
2.43 |
7,866 |
19,112 |
80,022 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 09 '26 |
Sale |
2.39 |
889 |
2,127 |
79,133 |
| Vultaggio Vincent | PAO and PFO |
Feb 02 '26 |
Sale |
2.55 |
2,540 |
6,477 |
187,286 |
| Vultaggio Vincent | PAO and PFO |
Feb 03 '26 |
Sale |
2.52 |
556 |
1,398 |
186,730 |
| WALTERS GROUP | 10% Owner |
Dec 31 '25 |
Buy |
1.20 |
6,459,973 |
7,751,968 |
13,509,973 |
| Matrix Capital Management Comp | 10% Owner |
Dec 15 '25 |
Sale |
1.33 |
7,500,000 |
9,975,000 |
6,459,973 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):